Lineage Cell Therapeutics (LCTX) Stock Price
Lineage Cell Therapeutics Price
Revenue has compounded at 14.2% per year over the past 19 years to 14.56 M USD. Lineage Cell Therapeutics's net margin stands at -436.5%, up from -1,104.2% several years earlier. Analysts set a median price target of 3.06 USD, implying 221.2% above the current price. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus.
Lineage Cell Therapeutics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Lineage Cell Therapeutics business model & stock analysis
Frequently asked questions about Lineage Cell Therapeutics
Lineage Cell Therapeutics Inc is a biotechnology company focused on developing innovative cell therapies for various medical conditions. Their business model revolves around utilizing their proprietary cell-based technology platform to create therapeutic products that address unmet medical needs. By harnessing the potential of pluripotent stem cells, Lineage aims to develop and commercialize novel therapies that can restore or replace damaged or dysfunctional cells in the body. This approach has the potential to revolutionize the treatment of diseases such as Parkinson's, spinal cord injury, macular degeneration, and more. Through strategic collaborations and partnerships, Lineage Cell Therapeutics Inc aims to advance their pipeline of cell therapy candidates and bring transformative treatments to patients in need.
Lineage Cell Therapeutics Inc is primarily active in the biotechnology and regenerative medicine industries.
The main competitors of Lineage Cell Therapeutics Inc in the market are reputable companies such as Fate Therapeutics Inc, bluebird bio Inc, and Celularity Inc.
Lineage Cell Therapeutics Inc, formerly known as BioTime Inc, is a clinical-stage biotechnology company focused on developing novel cell therapies for various diseases. With a rich history dating back to 1992, the company has been at the forefront of regenerative medicine research. Lineage Cell Therapeutics is dedicated to using its proprietary cell-based technologies to treat degenerative disorders and diseases. The company's extensive research expertise and collaborations have contributed to groundbreaking advancements in stem cell therapy. By leveraging its broad portfolio of cell lines, including pluripotent and progenitor cells, Lineage Cell Therapeutics aims to revolutionize the field of regenerative medicine and improve patient outcomes.
Lineage Cell Therapeutics Inc, a leading biotechnology company, has achieved significant milestones in its journey. The company has made breakthrough advancements in the field of cell therapy, focusing on regenerative medicine and developing innovative treatments for degenerative diseases. Lineage Cell Therapeutics has successfully completed multiple clinical trials, demonstrating the safety and efficacy of its promising cell-based therapies. Additionally, the company has gained regulatory approvals and collaborated with renowned medical institutions to further its research and development efforts. With a dedicated team of experts and a commitment to improving patients' lives, Lineage Cell Therapeutics continues to make strides in the field of regenerative medicine.
Lineage Cell Therapeutics Inc is primarily present in the United States.
Lineage Cell Therapeutics Inc represents values of innovation, dedication, and excellence in the field of cell therapy. The company's corporate philosophy revolves around utilizing the potential of stem cells to address unmet medical needs and improve patients' lives. With a focus on research and development, Lineage Cell Therapeutics Inc aims to deliver groundbreaking therapies that can revolutionize the treatment of age-related macular degeneration and other degenerative diseases. By harnessing the power of regenerative medicine, the company strives to offer hope and a better quality of life for patients worldwide.
13 analysts currently rate the Lineage Cell Therapeutics stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Lineage Cell Therapeutics to generate revenue of 15.16 M USD and earnings per share of -0.06 USD.
Converted at the current exchange rate, the Lineage Cell Therapeutics share trades at 0.85 EUR (0.95 USD).
The Lineage Cell Therapeutics share (LCTX) is listed on 3 stock exchanges, including: Frankfurt (BT3.F).
Lineage Cell Therapeutics Inc is a US-based company specializing in the development of cell therapies for the treatment of various diseases. The company's business model is based on the production and marketing of cell therapies derived from human embryonic stem cells. The company has various divisions, including neurology, ophthalmology, immunology, and oncology. In neuroscience, the company focuses on the therapy of spinal cord injuries, strokes, Alzheimer's disease, and other neurodegenerative diseases. In ophthalmology, the company focuses on the treatment of retinal diseases such as age-related macular degeneration and diabetic retinopathy. In immunology, Lineage Cell Therapeutics focuses on the treatment of autoimmune diseases such as type 1 diabetes and multiple sclerosis. In oncology, the company focuses on the development of cancer immunotherapies. The flagship product of Lineage Cell Therapeutics is OpRegen, a cell therapy for the treatment of retinal diseases. OpRegen is a product derived from pluripotent stem cells. It is currently in clinical trials, and the company hopes to bring it to market in the near future. Another product of Lineage Cell Therapeutics is OPC1, a cell therapy for the treatment of spinal cord injuries. OPC1 utilizes human embryonic stem cells differentiated into oligodendrocytes to repair damaged nerve fibers in the spinal cord. The product is currently in phase 1/2 studies. Lineage Cell Therapeutics is also working on the development of cancer immunotherapies based on the use of genetically modified T cells that can recognize and attack cancer cells. These therapies aim to provide more effective and targeted treatment for cancer. The company's business model involves the development and marketing of cell therapies derived from human embryonic stem cells. Lineage Cell Therapeutics works closely with academic institutions and research partners to develop new treatments and expand therapy options for patients. To further expand its business model, the company has undertaken various strategic partnerships and acquisitions. In 2018, Lineage Cell Therapeutics acquired Asterias Biotherapeutics to strengthen its position in the treatment of spinal cord injuries. In the same year, the company also entered into a partnership with Cancer Research UK to develop new cancer immunotherapies. In summary, Lineage Cell Therapeutics Inc is a company specializing in the development and marketing of cell therapies for the treatment of various diseases. The company's business model is based on the use of human embryonic stem cells and a diverse product portfolio encompassing various divisions, including neuroscience, ophthalmology, immunology, and oncology. Through strategic partnerships and acquisitions, the company aims to strengthen its position in the industry and continue its mission to develop innovative treatment options for patients in need.
The expected revenue of Lineage Cell Therapeutics is 15.16 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Lineage Cell Therapeutics is -13.48 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Lineage Cell Therapeutics is currently -16.27. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lineage Cell Therapeutics stock.
The price-to-sales ratio (P/S) of Lineage Cell Therapeutics is currently 14.46. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lineage Cell Therapeutics stock.
The Eulerpool Quality Score for Lineage Cell Therapeutics is 3/10.
The ISIN of Lineage Cell Therapeutics is US53566P1093. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Lineage Cell Therapeutics is A2PP89. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Lineage Cell Therapeutics is LCTX. The ticker symbol is used to trade Lineage Cell Therapeutics shares on the stock exchange.
Lineage Cell Therapeutics stock
Lineage Cell Therapeutics Peer Group
Lineage Cell Therapeutics Ticker
Lineage Cell Therapeutics FIGI
All fundamentals and in-depth analysis of Lineage Cell Therapeutics
Our stock analysis for Lineage Cell Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lineage Cell Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.